Work

Prothrombotic mutations and ischaemic stroke at a young age in two sisters

Year: 1998

Type: article

Abstract: median value of 93 ml (95% confidence interval 45.0-170 (p=0.001)).After saline the cystometric bladder capacity did not change significantly.No significant changes were found in blood pressures or pulse rates.No side eVects were reported by any patient.Atropine was not detected in blood samples 2 hours after intravesical instillation (limit of detection 0.05 mg/l).This early study provides evidence in favour of the eYcacy of intravesical atropine in increasing the cystometric bladder capacity in patients with multiple sclerosis.Cystometric bladder capacity was chosen as an outcome measure because it has been shown to be sensitive to the influence of orally administered antimuscarinic drugs used for the treatment of detrusor hyperreflexia in multiple sclerosis. 4 It is therefore likely that urgency and urge incontinence will be improved with the administration of intravesical atropine.However, this will require testing in a randomised controlled therapeutic trial.The patients did not identify any side eVects during the 2 hours after the administration of the atropine.It has been shown that orally administered oxybutynin will induce antimuscarinic side eVects in a similar period. 5 The absence of measurable drug in the blood at the time of the clinical eVect is encouraging.The results show promise and if clinical eYcacy were demonstrated this approach would be a useful addition to the therapeutic options for urinary incontinence in multiple sclerosis.

Source: Journal of Neurology Neurosurgery & Psychiatry

DOI: 10.1136/jnnp.65.6.958